With the improving knowledge of CML and its management, the goals of therapy need to be
revisited to ensure an optimal use of the BCR:: ABL1 TKIs in the frontline and later-line …

Simple Summary Chronic myeloid leukemia (CML) is a myeloproliferative neoplasia
associated with a molecular alteration, the fusion gene BCR-ABL1, that encodes the tyrosine …

Patients with chronic myeloid leukemia in chronic phase (CML-CP) resistant/intolerant to≥ 2
tyrosine kinase inhibitors (TKIs) are at high risk of experiencing poor outcomes because of …

Asciminib, the first BCR:: ABL1 inhibitor that S pecifically T argets the A BL M yristoyl P ocket
(STAMP), is approved worldwide for the treatment of adults with Philadelphia chromosome …

Overcoming multidrug resistance represents a major challenge for cancer treatment. In the
search for new chemotherapeutics to treat malignant diseases, drug repurposing gained a …

Asciminib is approved for patients with Philadelphia chromosome–positive chronic-phase
chronic myeloid leukemia (CML-CP) who received≥ 2 prior tyrosine kinase inhibitors or …

Dear Editor, Despite the excellent overall survival (OS) of chronic myeloid leukemia (CML)
patients, a significant proportion will fail currently available tyrosine-kinase inhibitors (TKIs) …

Chronic myeloid leukemia (CML) is driven by a translocation event between chromosomes 9
and 22, leading to the formation of a constitutively active BCR-ABL1 oncoprotein. Approved …

Failure of second-generation tyrosine kinase inhibitors (2GTKI) is a challenging situation in
patients with chronic myeloid leukemia (CML). Asciminib, recently approved by the US …

Background Patients with newly diagnosed chronic myeloid leukemia (CML) need long-term
therapy with high efficacy and safety. Asciminib, a BCR:: ABL1 inhibitor specifically targeting …